PMC:7243778 / 23961-25859
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
602 | 0-10 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
603 | 37-45 | Species | denotes | patients | Tax:9606 |
604 | 219-227 | Species | denotes | patients | Tax:9606 |
605 | 440-448 | Species | denotes | patients | Tax:9606 |
606 | 473-481 | Species | denotes | patients | Tax:9606 |
607 | 488-495 | Species | denotes | Patient | Tax:9606 |
608 | 541-551 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
609 | 583-590 | Species | denotes | persons | Tax:9606 |
610 | 592-600 | Species | denotes | Patients | Tax:9606 |
611 | 863-871 | Species | denotes | patients | Tax:9606 |
612 | 967-972 | Species | denotes | Ebola | Tax:1570291 |
613 | 976-984 | Species | denotes | SARS-CoV | Tax:694009 |
614 | 1029-1034 | Species | denotes | human | Tax:9606 |
615 | 1376-1384 | Species | denotes | patients | Tax:9606 |
616 | 1390-1400 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
617 | 1445-1453 | Species | denotes | patients | Tax:9606 |
618 | 1461-1469 | Species | denotes | patients | Tax:9606 |
619 | 1547-1555 | Species | denotes | patients | Tax:9606 |
620 | 956-965 | Species | denotes | influenza | Tax:11308 |
621 | 842-850 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T102 | 112-115 | Body_part | denotes | IgG | http://purl.org/sig/ont/fma/fma62872 |
T103 | 321-324 | Body_part | denotes | IgG | http://purl.org/sig/ont/fma/fma62872 |
T104 | 411-414 | Body_part | denotes | IgG | http://purl.org/sig/ont/fma/fma62872 |
T105 | 415-423 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
T106 | 651-659 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
T107 | 764-772 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
T108 | 790-796 | Body_part | denotes | plasma | http://purl.org/sig/ont/fma/fma62970 |
T109 | 1275-1281 | Body_part | denotes | plasma | http://purl.org/sig/ont/fma/fma62970 |
T110 | 1343-1351 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
T111 | 1595-1601 | Body_part | denotes | plasma | http://purl.org/sig/ont/fma/fma62970 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T93 | 0-8 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T94 | 541-549 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T95 | 842-850 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T96 | 956-965 | Disease | denotes | influenza | http://purl.obolibrary.org/obo/MONDO_0005812 |
T97 | 967-972 | Disease | denotes | Ebola | http://purl.obolibrary.org/obo/MONDO_0005737 |
T98 | 976-984 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T99 | 1089-1099 | Disease | denotes | infectious | http://purl.obolibrary.org/obo/MONDO_0005550 |
T100 | 1390-1398 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T303 | 433-439 | http://purl.obolibrary.org/obo/UBERON_0003100 | denotes | female |
T304 | 468-472 | http://purl.obolibrary.org/obo/UBERON_0003101 | denotes | male |
T305 | 468-472 | http://www.ebi.ac.uk/efo/EFO_0000970 | denotes | male |
T306 | 606-607 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T307 | 642-643 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T308 | 704-705 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T309 | 790-796 | http://purl.obolibrary.org/obo/UBERON_0001969 | denotes | plasma |
T310 | 872-875 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
T311 | 881-887 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | tested |
T312 | 905-911 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | tested |
T313 | 940-947 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | viruses |
T314 | 1029-1034 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | human |
T315 | 1275-1281 | http://purl.obolibrary.org/obo/UBERON_0001969 | denotes | plasma |
T316 | 1441-1444 | http://purl.obolibrary.org/obo/CLO_0050884 | denotes | ten |
T317 | 1475-1480 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T318 | 1595-1601 | http://purl.obolibrary.org/obo/UBERON_0001969 | denotes | plasma |
T319 | 1607-1608 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T320 | 1880-1881 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T142 | 468-472 | Chemical | denotes | male | http://purl.obolibrary.org/obo/CHEBI_30780 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T185 | 0-213 | Sentence | denotes | SARS-CoV-2 nAbs could be detected in patients from 10 to 15 days after symptoms onset and the positive rate for IgG reached close to 100% around 20 days [81,82] with the highest level during day 31–40 since onset. |
T186 | 214-307 | Sentence | denotes | Some patients (5.7%) had neutralizing Abs titers under the detectable level (ID50: <40) [83]. |
T187 | 308-398 | Sentence | denotes | The level of IgG antibodies was different between gender, age and clinical classification. |
T188 | 399-487 | Sentence | denotes | The average IgG antibody level in female patients was higher than in male patients [84]. |
T189 | 488-591 | Sentence | denotes | Patient over 40 years old developed higher levels of SARS-CoV-2 specific nAbs than the younger persons. |
T190 | 592-671 | Sentence | denotes | Patients with a worse clinical classification had a higher antibody titer [83]. |
T191 | 672-751 | Sentence | denotes | This remark is useful to select a research candidate and to save research time. |
T192 | 752-888 | Sentence | denotes | The passive antibody therapy, such as plasma fusion containing polyclonal antibodies from COVID-19 neutralized patients has been tested. |
T193 | 889-1016 | Sentence | denotes | This method was tested as an option to treat other viruses such as influenza, Ebola or SARS-CoV [[85], [86], [87], [88], [89]]. |
T194 | 1017-1127 | Sentence | denotes | The lack of human sera, and the possibility of contamination with other infectious agents limit this strategy. |
T195 | 1128-1233 | Sentence | denotes | However, several groups have reported some positive results demonstrating the potential of this approach. |
T196 | 1234-1434 | Sentence | denotes | After one dose of 200 mL of convalescent plasma derived from recently recovered donors with the neutralizing antibody titers above 1:640, the patients with SARS-CoV-2 positive revealed an improvement. |
T197 | 1435-1512 | Sentence | denotes | Among ten patients, seven patients were virus-negative post transfusion [90]. |
T198 | 1513-1692 | Sentence | denotes | Whereas in another study, among 5 patients received transfusion with convalescent plasma with a neutralization titer >40, 3 have been discharged from the hospital (length of stay: |
T199 | 1693-1779 | Sentence | denotes | 53, 51, and 55 days), and 2 are in stable condition at 37 days after transfusion [91]. |
T200 | 1780-1898 | Sentence | denotes | More studies might brighter this approach but evaluation in clinical trials are also still far from a bold conclusion. |
2_test
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
32450171-12777656-66454505 | 987-989 | 12777656 | denotes | 85 |
32450171-17914053-66454506 | 993-995 | 17914053 | denotes | 86 |
32450171-26735992-66454507 | 999-1001 | 26735992 | denotes | 87 |
32450171-15214887-66454508 | 1005-1007 | 15214887 | denotes | 88 |
32450171-15616839-66454509 | 1011-1013 | 15616839 | denotes | 89 |
32450171-32253318-66454510 | 1508-1510 | 32253318 | denotes | 90 |